NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

The 99 were randomized to receive injections of placebo prior to progression while the 233 received injections of DCVax-L prior to progression. The 99 lived longer.

Wrong. All the 331 DCVax-L trial patients received placebo prior to progression as did their matched ECAs but in addition to that, 232 trial patients (the treatment group) also received DCVax-L prior to progression, 64 trial patients received DCVax-L after progression and 29 trial patients failed to received DCVax-L before or after progression, most likely because most of them were rapid progressors and would have not have benefited from the vaccine.

The mOS of the 232 trial patients receiving the vaccine before progression was significantly longer than the mOS of the matched ECAs and the mOS of the 64 crossovers was even longer than the mOS of the 232 treatment patients. The longer mOS of those 232+64 patients can only be attributed to the administration of DCVax-L. The 29 trial patients whose mOS was likely much shorter than the mOS of the placebos, were most likely at a disadvantage because they were fast progressors who would no longer have been able to benefit from DCVax-L.